Weightloss varies by individual, but drug study results can give us a general idea. For example, a 2022 study of tirzepatide (the active ingredient in Mounjaro) prescribed for obesity ...
Weight-loss, however, is just the start. In March, semaglutide was approved in the US to treat cardiovascular disease in overweight individuals, and in April, tirzepatide (Mounjaro) showed ...
Pharmaceutical giants Eli Lilly and Novo Nordisk, makers of Zepbound and Wegovy, respectively, have filed lawsuits against medical spas, weight-loss clinics, and compounding pharmacies they accuse of ...